Gene Therapy
Vectors
Inspired By Nature – Motivated by Health
What we offer
Unique approach
AAV Peptide display, combined with unique DNA barcoding and next generation sequencing allows for easy screening of AAV libraries containing millions of rationally designed, targeted AAV variants in a single screen.
Fast & Flexible
Choose your target, tissue type, cell population or application. rAAVen designs a targeted, rationally designed AAV peptide display library which can be combined by a generated library of promotor & enhancer elements for increased cell and tissue specific expression.
Translational at scale
rAAVen offers screening of the AAV peptide library in animal models ranging from rodents to non-human primates, ensuring that the delivered product translates within mammalian species and are prime candidates for clinical trials.
Advancing Gene Therapy Through Collaboration
At rAAVen Therapeutics, we are proud to collaborate with industry leaders and innovators to advance the frontiers of gene therapy. Our partners are integral to our mission of developing cutting-edge solutions and driving impactful change in the field of adeno-associated virus (AAV) technologies.
Partner with us
We love to connect with innovators who share our dedication to develop revolutionary gene therapies.
rAAVen News
rAAVen and Cellevate Partner on AAV Library Testing
Together with fellow SmiLe Incubator alumni community member Cellevate, rAAVen Therapeutics announces the start of a shared project. Within this project rAAVen will design and
rAAVen Welcomes Yuriy Pomeshchik as Director of In Vitro
rAAVen Therapeutics announces the hiring of Yuriy Pomeshchik MD, PhD as Director of In Vitro. Before joining rAAVen, Yuriy held a position as Associate Researcher
rAAVen to Present at #ASGCT2024 and Myrtelle Symposium
rAAVen Therapeutics is pleased to share the news on our participation in this year’s #ASGCT2024, and the symposium held by Myrtelle, Inc., where we will